Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lung Neoplasms 9Carcinoma, Non-Small-Cell Lung 8Prostatic Neoplasms 6Glioblastoma 4Colorectal Neoplasms 4Breast Neoplasms 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Melanoma 2Lymphoma, Follicular 2Lymphoma 2Hodgkin Disease 2Ganglioneuroblastoma 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Astrocytoma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

ribociclib 1exemestane 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Letrozole 1Drug Therapy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Anatomic Stage II Breast Cancer AJCC v8 × Magnetic Resonance Spectroscopy × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡